Webinar | Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells
Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells
Tuesday, November 6, 2018 View registration for sessions available Presented by:
Matthew Robers Senior Research Scientist and Group Leader, Promega Corporation
Kelvin Lam Senior Director of Business Development, Reaction Biology Corporation
Learn how to overcome the limitations of current cell-based kinase assays by enabling quantitation of kinase-inhibitor occupancy and affinity in live cells.
In addition, learn about the collaboration between Promega and Reaction Biology Corporation resulting in conversion of BRET-based kinase target engagement assays into a service compatible with high-throughput cell-based profiling.